Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7049389 add-on study in chronic hepatitis B
2019-001139-30Phase 2Completed
- Sponsor
- Roche
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of linvencorvir in Chronic Hepatitis B (CHB) (4 arms), sponsored by Roche. Primary endpoint: Functional cure at 24 weeks post-treatment. Started May 2019; status: completed.
02
Drugs
linvencorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2019-001139-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001139-30.